Dr. Mark Payne, a professor of pediatrics at the Indiana University School of Medicine and a pediatric cardiologist at Riley ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

(RTTNews) - Biogen Inc. (BIIB) said that the European Commission has authorized Skyclarys (omaveloxolone) for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.

Levacetylleucine significantly improves neurological symptoms and functioning in patients with ataxia-telangiectasia, according to results from the IB1001-303 clinical trial. Topline results were ...

Ataxia affects the nervous system, disrupting muscle control, coordination, and balance. It can be hereditary, acquired, or sporadic, with each type requiring different diagnostic methods and care ...

Only successful pivotal Phase III trial in Ataxia-Telangiectasia (A-T), a rare, progressive neurodegenerative disease with no approved treatments Phase III trial successfully achieved its primary ...

“Friedreich's ataxia is a debilitating neuromuscular disease that progressively robs patients of their mobility and independence,” said Susan Perlman, MD, Clinical Professor, Department of Neurology, ...

Lexeo Therapeutics, Inc. has received Breakthrough Therapy designation from the FDA for its treatment LX2006, which shows promising interim clinical data in improving cardiac and neurologic measures ...

Ataxia is more than just clumsiness—it’s a neurological condition that affects coordination, balance, speech, and even vision ...

Moreover, Friedreich's ataxia treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the Friedreich's ataxia market growth may be offset by ...

Treatment goals for Friedreich ataxia include symptom management, slowing disease progression, and enhancing quality of life through multidisciplinary care. Supportive therapies address comorbidities ...

WASHINGTON (7News) — Bill Nye, one of the nation's most popular scientists is headed to Capitol Hill to bring awareness to the rare neurological disease Ataxia. The dedicated scientist is teaming up ...